Trial · NCT02586155
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of First Occurrence of Adjudication-confirmed Narrowly Defined MACE | 120 weeks | Incidence of first occurrence of MACE narrowly defined as a single composite endpoint of Cardiovascular (CV) Death (including undetermined cause of death) or Non-fatal Myocardial Infarction (MI) or Stroke. If a subject has multiple events, only the first event contributing to the composite endpoint is counted. |
| Secondary | Incidence of First Occurrence of Adjudication-confirmed Broadly Defined MACE | 120 weeks | First occurrence of MACE broadly defined as a single composite endpoint of Cardiovascular Death (CVD) (including undetermined cause of death) or Non-fatal Myocardial Infarction (MI), Stroke, or Hospitalization for CVD events (including unstable angina and evidence of new or presumed new progressive obstructive coronary disease or emergency revascularization procedures at any time and urgent revascularization procedures ≥30 days after the index event as defined by Hicks et al., 2014) . If a subject has multiple events, only the first event contributing to the composite endpoint is counted. |
| Secondary | Incidence of Hospitalization for Congestive Heart Failure (CHF) | 120 weeks | |
| Secondary | Incidence of All-cause Mortality | 120 weeks | |
| Secondary | Change in Apolipoprotein A1 (ApoA-I) Concentration From Baseline Over Time Within and Between Treatment Groups | 120 weeks | |
| Secondary | Change in Apolipoprotein B (apoB) Concentration From Baseline Over Time Within and Between Treatment Groups | 120 weeks | |
| Secondary | Change in LDL-C Concentration From Baseline Over Time Within and Between Treatment Groups | 120 weeks | |
| Secondary | Change in HDL-C Concentration From Baseline Over Time Within and Between Treatment Groups | 120 weeks | |
| Secondary | Change in Triglyceride (TG) Concentration From Baseline Over Time Within and Between Treatment Groups | 120 weeks | |
| Secondary | Change in Hemoglobin (Hb) A1c From Baseline Over Time Within and Between Treatment Groups | 120 weeks | |
| Secondary | Change in Glucose From Baseline Over Time Between and Within Treatment Groups | 120 weeks | |
| Secondary | Change in Alkaline Phosphatase (ALP) From Baseline Over Time Within and Between Treatment Groups | 172 weeks | |
| Secondary | Change in C Reactive Protein (CRP) Concentration From Baseline Over Time Within and Between Treatment Groups | 52 weeks | |
| Secondary | Change in Estimated Glomerular Filtration Rate (eGFR) From Baseline Over Time Within and Between Treatment Groups for Subjects With Impaired Renal Function at Baseline (eGFR <60 mL/Min/1.7m2) | 120 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02586155/registered